Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology
Go back to Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1164.49 +28.12 (2.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1136.37 | 52 Week High | $88.16 | |||
| Open | $1139.71 | 52 Week Low | $67.88 | |||
| Day High | $1170.12 | P/E | 269.56 | |||
| Day Low | $1125.64 | EPS | $4.32 | |||
| Volume | 1,483,342 | |||||
